Strategic Focus Clinical-stage biotechnology company specializing in serine hydrolase inhibitors with an emphasis on CNS pathways; potential for partnering on translational programs and first-in-class targets that align with neurology and neuropathic pain indications.

Acquisition Background Previously acquired by Lundbeck for 250M, indicating a history of strategic exits and potential appetite for continued collaboration or licensing deals around Abide’s CNS targets and proprietary compounds.

Key Leadership Experience in executive leadership and strategic roles (COO, CFO/Strategy) with board ties including notable scientists; leverage these connections for co-development discussions, joint ventures, or advisory-backed partnerships.

Clinical Pathways Early to mid-stage clinical programs (Tourette’s and neuropathic pain) suggest opportunities for milestone-driven partnerships, out-licensing of compounds, or collaboration on companion diagnostics and biomarker strategies.

Funding & Scale Small company with limited revenue and modest funding; potential fit for strategic collaborations, milestone-based financing, or sum-of-punding partnerships to de-risk late-stage development and accelerate value realization.